Health Canada approves MedMira’s Reveal® Rapid TP Test – Urgent New Tool In The Battle Against Syphilis

Halifax, Nova Scotia, 26 August 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received approval from Health Canada for its Reveal® TP (Syphilis) Antibody Test (Reveal® TP) – the fastest standalone screening device for syphilis in Canada. A vital point-of-care tool for healthcare professionals, Reveal® TP is a crucial advancement in […]
MedMira Receives Investigational Testing Authorizations for Multiplo® TP/HIV Self-Test and Non-Professional Use Applications

Halifax, Nova Scotia, 21st of January, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received Investigational Testing Authorizations (ITAs) from Health Canada to begin clinical trials for new label claim applications of its recently Health Canada approved Multiplo® TP/HIV rapid test. These applications include use as a self-test and for non-professional […]
MedMira receives investigational testing authorization for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test

Halifax, Nova Scotia, 9 January, 2025 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announced that its received investigational testing authorization (ITA) from Health Canada to begin clinical trials for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP), a cutting edge device that can determine active and non-active syphilis. The upcoming trials will be led […]
MedMira receives Health Canada approval for its Multiplo® Rapid (TP/HIV) Test for Syphilis and HIV

Halifax, Nova Scotia – December 24, 2024 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received today, on December 24, 2024, the approval from Health Canada for its Multiplo® Rapid TP/HIV Test (Multiplo® TP/HIV) to be rolled out across Canada, a critical point-of-care tool to address the health crises with HIV and […]
Clinical Trials to get Underway with Multiplo® Complete Syphilis (TP/nTP) Antibody Test – A Potential Game Changer to Address Syphilis Health Crisis in Canada

Halifax, Nova Scotia, 13 August, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces it will conduct full clinical trials for its unique Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP) with the goal of getting it licensed in Canada. The new Multiplo® TP/nTP will provide a complete system which combines screening and confirmation in […]
Update on MedMira’s Reveal® TP (Syphilis) Clinical Trials in Canada

Halifax, Nova Scotia, 14 March, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its progress to achieve regulatory approval in Canada for its Reveal® TP (Syphilis) antibody test. The Company has successfully started its clinical trials in Saskatchewan in early March 2023 and commences another trial in British Colombia by the […]
New development of gold nano-particles

MedMira is continuously developing more ways to expand on future potentials of its RVF Technology, if this is customer satisfaction, increase of output or supporting regulatory for additional claims. In collaboration with researchers, Dr. Xu Zhang and Dr. Andrew Carrier at Cape Brenton University, and with the great support of NSBI (Nova Scotia Business Inc […]